Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | DGAT2 | Q96PD7 | 6/20 | 0.38 |
| ▸ | BTK | Q06187 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 10/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5668095 | 1.00 | ALDH1A1 (0.38) | ALDH1A1DGAT2BTKCHRM1 | |
| SCHEMBL5667034 | 1.00 | ALDH1A1 (0.38) | ALDH1A1DGAT2BTKCHRM1 | |
| SCHEMBL5669017 | 0.85 | ALDH1A1 (0.41) | ALDH1A1BTK | |
| SCHEMBL5667930 | 0.84 | ACKR3 (0.41) | ALDH1A1 | |
| SCHEMBL5669375 | 0.84 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL2958234 | 0.83 | CHEK1 (0.44) | ALDH1A1BTK | |
| SCHEMBL5667324 | 0.83 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL5668146 | 0.83 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL5669360 | 0.83 | BTK (0.39) | ALDH1A1BTK | |
| SCHEMBL5669394 | 0.83 | BTK (0.39) | ALDH1A1BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060247269-A1 | Thienopyridone derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2006-11-02 | — | — | US | claimed |
| US-20060247269-A1 | Thienopyridone derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247269-A1 | Thienopyridone derivatives as kinase inhibitors | MAPKAPK2, MAP3K6, MAP3K12 | ALDH1A1 2307/4885DGAT2 4434/4885BTK 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.